A Medical Device Daily
John Rush has resigned his position as president/CEO of Sanaurus (Pleasanton, California) to become president/CEO of North American Scientific (NAS; Chatsworth, California).
Rush will begin his new position in mid-April and is expected to join the company's board. He succeeds L. Michael Cutrer, president/CEO since the company's launch in 1989. Cutrer will become executive VP and chief technology officer and serve as a board member.
John Howe has been promoted from chief operating and CFO to president/CEO of Sanaurus. Prior to joining Sanaurus, Howe was CFO for Eunoe.
Rush has been president/CEO of Sanaurus Medical since 2002. Previously, he was president/CEO at Micro Therapeutics (now owned by ev3), a device company focused on the treatment of cerebral and peripheral vascular disorders worldwide.
NAS said that details of Rush's compensation will be disclosed "shortly."
Dr. Gary Wilner, non-executive chairman of NAS, said that Rush "brings a proven track record of product development and sales and marketing expertise in the medical device arena."
NAS, focused on radiation therapy, develops products that include its Prospera brachytherapy seeds and SurTRAK needles and strands used in the treatment of prostate cancer. The company said it plans to commercialize its ClearPath multi-channel catheter-breast brachytherapy devices in 2007, calling them the only devices approved for both high-dose and continuous release, or low-dose, radiation treatments.
Rush said, "I believe that my experience in the medical device industry, particularly as it relates to breast disease, will bring value to the company's efforts to launch its upcoming breast brachytherapy product, ClearPath."
Sanaurus is developing minimally invasive products for the diagnosis and treatment of breast disease using cryo-technologies designed for breast biopsy, tumor localization and ablation.